- Home
- LOAN vs CUE Comparison
LOAN vs CUE Comparison
Compare LOAN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOAN
- CUE
- Stock Information
- Founded
- LOAN 1989
- CUE 2014
- Country
- LOAN United States
- CUE United States
- Employees
- LOAN N/A
- CUE N/A
- Industry
- LOAN Real Estate Investment Trusts
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- LOAN Real Estate
- CUE Health Care
- Exchange
- LOAN Nasdaq
- CUE Nasdaq
- Market Cap
- LOAN 61.0M
- CUE 61.1M
- IPO Year
- LOAN 1999
- CUE 2018
- Fundamental
- Price
- LOAN $4.93
- CUE $0.71
- Analyst Decision
- LOAN
- CUE Strong Buy
- Analyst Count
- LOAN 0
- CUE 2
- Target Price
- LOAN N/A
- CUE $3.00
- AVG Volume (30 Days)
- LOAN 44.2K
- CUE 270.3K
- Earning Date
- LOAN 10-24-2025
- CUE 11-12-2025
- Dividend Yield
- LOAN 9.41%
- CUE N/A
- EPS Growth
- LOAN N/A
- CUE N/A
- EPS
- LOAN 0.46
- CUE N/A
- Revenue
- LOAN $7,138,128.00
- CUE $8,286,000.00
- Revenue This Year
- LOAN N/A
- CUE N/A
- Revenue Next Year
- LOAN $4.47
- CUE N/A
- P/E Ratio
- LOAN $10.56
- CUE N/A
- Revenue Growth
- LOAN N/A
- CUE N/A
- 52 Week Low
- LOAN $4.74
- CUE $0.54
- 52 Week High
- LOAN $6.05
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- LOAN 30.57
- CUE 41.54
- Support Level
- LOAN $4.83
- CUE $0.68
- Resistance Level
- LOAN $5.19
- CUE $0.81
- Average True Range (ATR)
- LOAN 0.12
- CUE 0.04
- MACD
- LOAN -0.04
- CUE -0.01
- Stochastic Oscillator
- LOAN 18.88
- CUE 20.26
About LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.